Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 451 to 500 of 2027

TitleReference numberPublishedLast updated
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Metastatic malignant disease of unknown primary origin in adults: diagnosis and managementCG104
Tezepelumab for treating severe asthmaTA880
Lumasiran for treating primary hyperoxaluria type 1HST25
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiencyHST26
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoeaHTG672
Endoscopic ultrasound-guided biliary drainage for biliary obstructionHTG673
Hypertension in pregnancy: diagnosis and managementNG133
AposHealth for knee osteoarthritisHTG671
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Percutaneous thoracic duct embolisation for persistent chyle leakHTG666
Focal therapy using high-intensity focused ultrasound for localised prostate cancerHTG667
Radiofrequency ablation for palliation of painful spinal metastasesHTG669
Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastasesHTG670
Maximal cytoreductive surgery for advanced ovarian cancerHTG668
UrgoStart for treating diabetic foot ulcers and leg ulcersHTG502
Finerenone for treating chronic kidney disease in type 2 diabetesTA877
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessmentHTG663
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Endoluminal gastroplication for gastro-oesophageal reflux diseaseHTG661
Percutaneous transluminal renal sympathetic denervation for resistant hypertensionHTG662
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Regorafenib for previously treated metastatic colorectal cancerTA866
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Transvenous obliteration for gastric varicesHTG658
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerHTG659
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Somatrogon for treating growth disturbance in children and young people aged 3 years and overTA863
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predictedTA864
Delirium: prevention, diagnosis and management in hospital and long-term careCG103
Maribavir for treating refractory cytomegalovirus infection after transplantTA860
Trabeculectomy with a biodegradable collagen matrix implant for glaucomaHTG656
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)TA859
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and educationNG213
MRI-based technologies for assessing non-alcoholic fatty liver diseaseHTG655
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinomaTA857

Results per page

  1. 10
  2. 25
  3. 50
  4. All